DSG3 and myasthenia gravis: Currently, two clinical trials are evaluating CAAR-T cell therapy targeting muscle-specific tyrosine kinase (MuSK) in myasthenia gravis and desmoglein-3 (Dsg-3) in mucosal-dominant pemphigus vulgaris (Table 2).